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A B S T R A C T  
Background: Meningiomas are slow growing intracranial and intraspinal neoplasms with a tendency to recur locally. WHO grades 
them as I (benign), II (atypical) and III (anaplastic) in order of their increasing aggressiveness, based on histological parameters and 
brain parenchymal invasion. Progesterone receptors (PR) are more prevalent amongst the lower grade meningiomas. The objective 
of this study was to determine the immunohistochemical expression of progesterone receptors in meningiomas of different grades. 
Material and Methods: A total of 100 cases were selected over a period of 2.5 years. Three to five microns’ thick sections stained 
with Hematoxylin and Eosin were examined microscopically by a team of two Histopathologists and graded into grades I, II and III, 
according to 2016 WHO classification criteria. Another section of the original tumor was stained with progesterone receptor antibody 
using the conventional immunoperoxidase method. Stained slides were than examined by the same team of Histopathologists and 
declared positive (if nuclear staining was observed in more than 10% of tumor cells) or negative. Statistical analysis was done using 
SPSS version 21. 
Results: Out of a total of 100 cases of meningioma, there were 79 cases of benign/typical WHO grade I, 15 cases of atypical/ WHO 
grade II and 6 cases of anaplastic/ WHO grade III tumor. PR status was positive in 89.8 % (71/79) of grade I meningiomas and 46.6 
% (7/15) of grade II/Atypical meningiomas. The 06 cases of Anaplastic/WHO grade III tumors were negative for PR. There was a 
higher prevalence of Progesterone receptors in female patients (89.8%; 53/59) as compared to male meningioma patients (60.9%; 
25/41). 
Conclusion: We observed a decreased expression of progesterone receptor in higher grades of meningioma in this study. It is an 
effort to explore conservative treatment options for inoperable lesions, as anti-progesterone therapy may hold a promise as a new 
treatment option in the near future. 
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I n t r o d u c t i o n  
 
Meningiomas are benign, slow growing, locally recurring 
intracranial and intraspinal neoplasms that are known to 
have sex steroid receptors expression.1-3 The discovery of 
such receptors was based on the association of 
meningiomas with female gender, breast cancers4, 
pregnancy related growth and luteal phase of menstrual 
cycle.5 Progesterone receptors status and proliferation 
indices are known prognostic indicators of meningiomas.6 
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Several studies indicate progesterone receptor correlation 
with gender , age  as well as WHO grades (I, II and III).4  
 
Regarding sex hormone receptors expressed in 
meningiomas, about 70% are progesterone receptors,7 
primarily associated with lower grade meningiomas. An 
Indian study assessing the PR status in different grades 
of meningiomas observed that 70% of grade I 
meningiomas in contrast to only 20% Grade II 
meningiomas, were PR Positive. There was a single 
grade III meningioma case in this study, which was 
reported as PR negative.6 Similarly recurrent 
meningiomas were characterized by a consistent 
negativity for progesterone receptors.8 Variable 
progesterone receptor expression is frequently seen in 
atypical group of meningiomas.9 The role of hormones, 
specifically progesterone, in pathogenesis of 
meningiomas is further highlighted by the two-fold greater 
occurrence of meningiomas in females, the hormonal 
status of female patients and the use of exogenous 
hormones as contraceptive pills (OC).10,11 
 
Although underestimated in the past, introduction of novel 
chemotherapeutic options suggests that treatment with 
anti-progesterone receptor agents may prove fruitful for 
selected patients.12 This study was conducted to 
demonstrate the occurrence of progesterone receptors in 
meningiomas as there is a limited number of studies 
available in our part of the world. 
 
M a t e r i a l  a n d  M e t h o d s  
This study was conducted in the Histopathology 
Department of Federal Government Polyclinic, PGMI, 
Islamabad from 1st January, 2013 to 30th June, 2015. It 
was a cross-sectional study with a sample size of 100, 
which was calculated by WHO sample size calculator. 
Consecutive non- probability sampling technique was 
employed including all cases reported as Meningiomas of 
any grade. Cases of both genders in age range of 25 to 
70 years were included. However, stereotactic biopsies, 
tissue exhibiting fixation artifacts and inadequate scant 
tissue were excluded. Freshly cut, three to five microns’ 
thick sections, stained with Hematoxylin and Eosin (H & 
E) were examined microscopically by a team of two 
Histopathologists (a Consultant and a Resident 
Histopathologist). All cases were graded according to 
WHO grading system. Another 6 microns thick section of 
the original tumor were stained with progesterone 
receptor antibody (anti-PR monoclonal antibodies 
purchased from DAKO) using the conventional 
immunoperoxidase method. Benign breast tissue was 
used as positive controls. Stained slides were than 
examined by the same team of Histopathologists and 
declared positive (if nuclear staining was observed in 
more than 10% of tumor cells) or negative for PR 
expression.11  
 
The data was entered in SPSS version 21. Frequency 
and percentages were used to calculate qualitative 
variables like presence or absence of progesterone 
receptors by use of immunohistochemistry in 
meningiomas and its grades. Mean and standard 
deviations were used to calculate quantitative variables 
like age of the patient. Tumor areas were first scanned on 
low-power for maximally stained regions and the stained 
nuclei were then counted at high-power magnification 
(40X). 
 
R e s u l t s  
A total of 100 patients, with the diagnosis of meningioma 
were included, in this study. Mean age of the patients was 
50.33 ± 12 years. Female predominance was observed 
with 59% females (n=59) and 41% males (n=41). 
According to WHO criteria, of all the subtypes of 
meningioma, the most commonly found entity was 
benign/typical WHO grade I tumors (n=79 cases), 
followed by atypical/grade II tumors (n=15 cases) and 
anaplastic/grade III tumors (n=6 cases), respectively. 
Brain invasion was found in 3% of cases and none of the 
cases were recurrent tumors.  
 
Overall the PR status was positive in 78% (n=78) of 
meningioma cases in this study, while PR expression was 
negative in all the three cases showing brain invasion. PR 
status was positive in 89.8 % (71/79) of grade I 
meningiomas and 46.6 % (7/15) of grade II/Atypical 
meningiomas. The 06 cases of Anaplastic/WHO grade III 
tumors were negative for PR (Figure 1). There was higher 
prevalence of Progesterone receptors in female patients 
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(89.8%; 53/59) as compared to male meningioma patients 
(60.9%; 25/41) as shown in Figure 2. 
 
Figure 1: Decreasing trend of PR expression in increasing grades 
of meningioma 
 
 
Figure 2: Gender distribution of PR positive and PR negative cases of 
meningioma. 
 
H&E stained tissue section of meningioma grade I along 
with Progesterone receptor strong nuclear positivity is 
shown in Figure 3. H&E stain of anaplastic meningioma 
grade -III, showing loss of whorling pattern, nuclear 
atypia, nuclear pleomorphism and high mitotic activity is 
shown in Figure 4, while Progesterone receptor negative 
staining is shown in Figure 5. 
 
 
Figure 3: Meningioma grade I showing meningothelial cells 
arranged in whorling/lobular pattern. PR IHC applied on the same 
case shows strong nuclear positivity. 
 
Figure 4: H&E stain of anaplastic meningioma grade-III, showing 
loss of whorling pattern, nuclear atypia & pleomorphism. 
 
 
Figure 5: Progesterone receptor IHC stain applied on the above case 
shows no nuclear staining with adequate controls applied. 
 
 
D i s c u s s i o n  
Meningiomas account for 20–32% of all the primary 
intracranial tumors. According to the WHO 2016 
classification system, meningiomas are classified into 3 
histological grades and 15 subtypes. This 
histopathological classification is generally used to predict 
the clinical course of meningioma.13 Even after complete 
removal, WHO grade I meningiomas frequently recur. The 
role of steroid hormones in the progression of 
meningiomas is still a matter of controversy. Our study 
aims to highlight the expression of PR in different grades 
of meningiomas. The results establish that 
immunodetection of progesterone receptors is inversely 
proportional to the histological grade of the tumor. Hence 
this can be used for assessing the biological behavior of 
meningiomas. Statistics of this study are similar to several 
other studies, which concluded a more favorable 
prognosis for PR positive meningiomas.10,11 
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Gender predilection for females in case of meningioma is 
evident in most of the studies available in the literature. In 
this study 59% of the patients were female while 41% 
were males. In a descriptive study conducted in France 
Nagashima and colleagues collected 13,038 cases of 
meningiomas. Among these 9769 (74.9%) were females 
and 3269 (25.1%) were males. This is in accordance with 
previously published data.14 According to the World Health 
Organization (WHO) classification, meningiomas are 
classified into three grades; grade I, II and III as already 
described. Studies showed that 90% of all meningiomas 
are benign tumors and 10% are in grade II or III, with 
unfavorable clinical courses. This synchronizes with our 
data and several other studies.15 
We observed that PR expression was higher in grade I 
tumors than grade II and III tumors. These findings are 
also in concordance to published literature. Similar 
findings were noted by Iplikcioglu and colleagues who 
found that PR expression was higher in WHO grade I 
meningiomas than grade II and III.16 Cahill et al and 
Brandis et al showed that malignant meningiomas are 
devoid of PR and estrogen receptors. Furthermore, 
Whittle et al reported that PR negative meningiomas were 
biologically more aggressive than PR positive 
meningiomas.17 Our data confirms the presence of 
significantly higher PR values in benign meningiomas 
compared with WHO grade II or III tumors. The PR 
expression exhibits marked heterogenicity within the 
same tumor, owing to the various innovative surgical 
procedures applied as well as intrinsic heterogeneous 
nature of the tumor itself.10 
 
In addition, our study observed that PR expression was 
more in female gender than males. In 89.8% of female 
patients, Progesterone receptors were found in 
meningiomas while it was present in 60.9% of male 
patients. Perrot-Applanat and colleagues also found 
similar findings that progesterone receptors were 
immunostained in 79% of female patients in contrast to 
58% of male patients.18 Mukhopadhyay studied the PR 
expression along with ER and Ki -67 and found a 
reciprocal expression of PR and ER i.e. higher the grade 
of the tumor the more is the immunoreactivity for ER but 
PR expression was lost with higher grade.19 
 
One limitation of our study is that we were unable to 
follow up the patients to see the behavior of the tumor in 
vivo due to time constraints. 
 
C o n c l u s i o n  
Our study is a step towards better understanding of 
pathophysiology of meningioma. It supports the 
conservative management of meningioma through 
noninvasive hormonal therapy instead of surgery, which 
has its own complications. However, more work needs to 
be done, incorporating other clinical and histopathological 
parameters as well, so that newer treatment option of 
anti-progesterone therapy can be further explored.  
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